1
|
Bhattacharya P, Mandal A. Identification of amentoflavone as a potent SARS-CoV-2 M pro inhibitor: a combination of computational studies and in vitro biological evaluation. J Biomol Struct Dyn 2024:1-19. [PMID: 38263736 DOI: 10.1080/07391102.2024.2304676] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/17/2023] [Accepted: 01/07/2024] [Indexed: 01/25/2024]
Abstract
Small-molecule inhibitors of SARS-CoV-2 Mpro that block the active site pocket of the viral main protease have been considered potential therapeutics for the development of drugs against SARS-CoV-2. Here, we report the identification of amentoflavone (a biflavonoid) through docking-based virtual screening of a library comprised of 231 compounds consisting of flavonoids and isoflavonoids. The docking results were further substantiated through extensive analysis of the data obtained from all-atom 150 ns MD simulation. End-state effective free energy calculations using MM-PBSA calculations further suggested that (Ra)-amentoflavone (C3'-C8''-atropisomer) may show a greater binding affinity towards the Mpro than (Sa)-amentoflavone. In vitro cytotoxicity assay established that amentoflavone showed a high CC50 value indicating much lower toxicity. Further, potent inhibition of the Mpro by amentoflavone was established by studying the effect on HEK293T cells treated with SARS-CoV-2 Mpro expressing plasmid.Communicated by Ramaswamy H. Sarma.
Collapse
Affiliation(s)
| | - Anirban Mandal
- Department of Microbiology, Mrinalini Datta Mahavidyapith, Kolkata, India
| |
Collapse
|
2
|
Maurya AK, Agnihotri VK. Valeriana jatamansi: Bioactive Compounds and their Medicinal Uses. Curr Top Med Chem 2024; 24:757-796. [PMID: 38318825 DOI: 10.2174/0115680266273617240129042653] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/07/2023] [Revised: 12/16/2023] [Accepted: 12/28/2023] [Indexed: 02/07/2024]
Abstract
Valeriana jatamansi is a reputed perennial medicinal herb distributed throughout the world, where it is used in cytotoxicity, neuronal problems, insomnia, leishmania and acetylcholinesterase inhibitor, antioxidant, antiviral and α-glucosidase inhibition activities. This review describes the current state of chemical characterization of isolated metabolites, which are well accepted for the treatment of various ailments in the indigenous system of medicine. This comprehensive review covers previously published research articles and reviews up to 2023 with an emphasis on the structural characterization of isolated bioactive compounds using different analytical techniques. Furthermore, the present review also focuses on the detailed medicinal and pharmacological properties of isolated compounds from this threatened herb.
Collapse
Affiliation(s)
- Antim K Maurya
- Chemical Technology Division, CSIR-Institute of Himalayan Bioresource Technology, Palampur (Himachal Pradesh), 176061, India
- Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, 201002, India
- Department of BioMolecular Sciences, University of Mississippi, Oxford, Mississippi, USA
| | - Vijai K Agnihotri
- Chemical Technology Division, CSIR-Institute of Himalayan Bioresource Technology, Palampur (Himachal Pradesh), 176061, India
- Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, 201002, India
| |
Collapse
|
3
|
Li J, Li X, Wang C, Zhang M, Ye M, Wang Q. The potential of Valeriana as a traditional Chinese medicine: traditional clinical applications, bioactivities, and phytochemistry. Front Pharmacol 2022; 13:973138. [PMID: 36210806 PMCID: PMC9534556 DOI: 10.3389/fphar.2022.973138] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/19/2022] [Accepted: 08/26/2022] [Indexed: 01/30/2023] Open
Abstract
Valeriana plants are members of the Caprifoliaceae family, which include more than 200 species worldwide. We summarized previous reports on traditional clinical applications, bioactivities, and phytochemistry of Valeriana by searching electronic databases of Science Direct, Web of Science, PubMed, and some books. Some Valeriana species have been used as traditional medicines, demonstrating calming fright and tranquilizing mind, promoting Qi and blood, activating blood circulation and regulating menstruation, dispelling wind and eliminating dampness, regulating Qi-flowing to relieve pain, and promoting digestion and checking diarrhea, and treating diseases of the nervous, cardiovascular, and digestive systems, inflammation, gynecology, and others. Pharmacology studies revealed the effects of Valeriana, including sedative, hypnotic, antispasmodic, analgesic, antidepressant, anxiolytic, anticonvulsant, antiepileptic, neuroprotective, antibacterial, antiviral, cytotoxic, and antitumor effects as well as cardiovascular and cerebrovascular system improvements. More than 800 compounds have been isolated or identified from Valeriana, including iridoids, lignans, flavonoids, sesquiterpenoids, alkaloids, and essential oils. Constituents with neuroprotective, anti-inflammatory, cytotoxic, and sedative activities were also identified. However, at present, the developed drugs from Valeriana are far from sufficient. We further discussed the pharmacological effects, effective constituents, and mechanisms directly related to the traditional clinical applications of Valeriana, revealing that only several species and their essential oils were well developed to treat insomnia. To effectively promote the utilization of resources, more Valeriana species as well as their different medicinal parts should be the focus of future related studies. Clinical studies should be performed based on the traditional efficacies of Valeriana to facilitate their use in treating diseases of nervous, cardiovascular, and digestive systems, inflammation, and gynecology. Future studies should also focus on developing effective fractions or active compounds of Valeriana into new drugs to treat diseases associated with neurodegeneration, cardiovascular, and cerebrovascular, inflammation and tumors. Our review will promote the development and utilization of potential drugs in Valeriana and avoid wasting their medicinal resources.
Collapse
Affiliation(s)
- Jianchun Li
- Engineering Technology Research Center for Standardized Processing of Chinese Materia Medica, College of TCM, Guangdong Pharmaceutical University, Guangzhou, China
| | - Xiaoliang Li
- Key Laboratory of Tropical Translational Medicine of Ministry of Education, Hainan Provincial Key Laboratory for Research and Development of Tropical Herbs, Haikou Key Laboratory of Li Nationality Medicine, School of Pharmacy, Hainan Medical University, Haikou, China
| | - Changfu Wang
- Engineering Technology Research Center for Standardized Processing of Chinese Materia Medica, College of TCM, Guangdong Pharmaceutical University, Guangzhou, China
| | - Manli Zhang
- Engineering Technology Research Center for Standardized Processing of Chinese Materia Medica, College of TCM, Guangdong Pharmaceutical University, Guangzhou, China
| | - Minhui Ye
- Engineering Technology Research Center for Standardized Processing of Chinese Materia Medica, College of TCM, Guangdong Pharmaceutical University, Guangzhou, China
| | - Qiuhong Wang
- Engineering Technology Research Center for Standardized Processing of Chinese Materia Medica, College of TCM, Guangdong Pharmaceutical University, Guangzhou, China
| |
Collapse
|
4
|
Thomas E, Stewart LE, Darley BA, Pham AM, Esteban I, Panda SS. Plant-Based Natural Products and Extracts: Potential Source to Develop New Antiviral Drug Candidates. Molecules 2021; 26:6197. [PMID: 34684782 PMCID: PMC8537559 DOI: 10.3390/molecules26206197] [Citation(s) in RCA: 27] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/01/2021] [Revised: 10/06/2021] [Accepted: 10/11/2021] [Indexed: 12/17/2022] Open
Abstract
Viral infections are among the most complex medical problems and have been a major threat to the economy and global health. Several epidemics and pandemics have occurred due to viruses, which has led to a significant increase in mortality and morbidity rates. Natural products have always been an inspiration and source for new drug development because of their various uses. Among all-natural sources, plant sources are the most dominant for the discovery of new therapeutic agents due to their chemical and structural diversity. Despite the traditional use and potential source for drug development, natural products have gained little attention from large pharmaceutical industries. Several plant extracts and isolated compounds have been extensively studied and explored for antiviral properties against different strains of viruses. In this review, we have compiled antiviral plant extracts and natural products isolated from plants reported since 2015.
Collapse
Affiliation(s)
| | | | | | | | | | - Siva S. Panda
- Department of Chemistry & Physics, Augusta University, Augusta, GA 30912, USA; (E.T.); (L.E.S.); (B.A.D.); (A.M.P.); (I.E.)
| |
Collapse
|
5
|
Mandal A, Jha AK, Hazra B. Plant Products as Inhibitors of Coronavirus 3CL Protease. Front Pharmacol 2021; 12:583387. [PMID: 33767619 PMCID: PMC7985176 DOI: 10.3389/fphar.2021.583387] [Citation(s) in RCA: 25] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/14/2020] [Accepted: 01/19/2021] [Indexed: 12/23/2022] Open
Abstract
Background: The ongoing COVID-19 pandemic has created an alarming situation due to extensive loss of human lives and economy, posing enormous threat to global health security. Till date, no antiviral drug or vaccine against SARS-CoV-2 has reached the market, although a number of clinical trials are under way. The viral 3-chymotrypsin-like cysteine protease (3CLpro), playing pivotal roles in coronavirus replication and polyprotein processing, is essential for its life cycle. In fact, 3CLpro is already a proven drug discovery target for SARS- and MERS-CoVs. This underlines the importance of 3CL protease in the design of potent drugs against COVID-19. Methods: We have collected one hundred twenty-seven relevant literatures to prepare the review article. PubMed, Google Scholar and other scientific search engines were used to collect the literature based on keywords, like "SARS-CoVs-3CL protease," "medicinal plant and anti-SARS-CoVs-3CL protease" published during 2003-2020. However, earlier publications related to this topic are also cited for necessary illustration and discussion. Repetitive articles and non-English studies were excluded. Results: From the literature search, we have enlisted medicinal plants reported to inhibit coronavirus 3CL protease. Some of the plants like Isatis tinctoria L. (syn. Isatis indigotica Fort.), Torreya nucifera (L.) Siebold and Zucc., Psoralea corylifolia L., and Rheum palmatum L. have exhibited strong anti-3CLpro activity. We have also discussed about the phytochemicals with encouraging antiviral activity, such as, bavachinin, psoralidin, betulinic acid, curcumin and hinokinin, isolated from traditional medicinal plants. Conclusion: Currently, searching for a plant-derived novel drug with better therapeutic index is highly desirable due to lack of specific treatment for SARS-CoV-2. It is expected that in-depth evaluation of medicinally important plants would reveal new molecules with significant potential to inhibit coronavirus 3CL protease for development into approved antiviral drug against COVID-19 in future.
Collapse
Affiliation(s)
- Anirban Mandal
- Department of Microbiology, Mrinalini Datta Mahavidyapith, Kolkata, India
| | - Ajeet Kumar Jha
- Animal Health Research Division, Nepal Agricultural Research Council, Kathmandu, Nepal
| | - Banasri Hazra
- Department of Pharmaceutical Technology, Jadavpur University, Kolkata, India
| |
Collapse
|
6
|
Ahmad S, Zahiruddin S, Parveen B, Basist P, Parveen A, Gaurav, Parveen R, Ahmad M. Indian Medicinal Plants and Formulations and Their Potential Against COVID-19-Preclinical and Clinical Research. Front Pharmacol 2021; 11:578970. [PMID: 33737875 PMCID: PMC7962606 DOI: 10.3389/fphar.2020.578970] [Citation(s) in RCA: 79] [Impact Index Per Article: 19.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/01/2020] [Accepted: 12/29/2020] [Indexed: 12/11/2022] Open
Abstract
The cases of COVID-19 are still increasing day-by-day worldwide, even after a year of its first occurrence in Wuhan city of China. The spreading of SARS-CoV-2 infection is very fast and different from other SARS-CoV infections possibly due to structural differences in S proteins. The patients with severe diseases may die due to acute respiratory distress syndrome (ARDS) caused by systemic inflammatory reactions due to the excessive release of pro-inflammatory cytokines and chemokines by the immune effector cells. In India too, it is spreading very rapidly, although the case fatality rate is below 1.50% (https://www.statista.com), which is markedly less than in other countries, despite the dense population and minimal health infrastructure in rural areas. This may be due to the routine use of many immunomodulator medicinal plants and traditional AYUSH formulations by the Indian people. This communication reviews the AYUSH recommended formulations and their ingredients, routinely used medicinal plants and formulations by Indian population as well as other promising Indian medicinal plants, which can be tested against COVID-19. Special emphasis is placed on Indian medicinal plants reported for antiviral, immunomodulatory and anti-allergic/anti-inflammatory activities and they are categorized for prioritization in research on the basis of earlier reports. The traditional AYUSH medicines currently under clinical trials against COVID-19 are also discussed as well as furtherance of pre-clinical and clinical testing of the potential traditional medicines against COVID-19 and SARS-CoV-2. The results of the clinical studies on AYUSH drugs will guide the policymakers from the AYUSH systems of medicines to maneuver their policies for public health, provide information to the global scientific community and could form a platform for collaborative studies at national and global levels. It is thereby suggested that promising AYUSH formulations and Indian medicinal plants must be investigated on a priority basis to solve the current crisis.
Collapse
Affiliation(s)
- Sayeed Ahmad
- Bioactive Natural Product Laboratory, Department of Pharmacognosy and Phytochemistry, School of Pharmaceutical Education and Research, Jamia Hamdard (Deemed University), New Delhi, India
| | - Sultan Zahiruddin
- Bioactive Natural Product Laboratory, Department of Pharmacognosy and Phytochemistry, School of Pharmaceutical Education and Research, Jamia Hamdard (Deemed University), New Delhi, India
| | - Bushra Parveen
- Bioactive Natural Product Laboratory, Department of Pharmacognosy and Phytochemistry, School of Pharmaceutical Education and Research, Jamia Hamdard (Deemed University), New Delhi, India
| | - Parakh Basist
- Bioactive Natural Product Laboratory, Department of Pharmacognosy and Phytochemistry, School of Pharmaceutical Education and Research, Jamia Hamdard (Deemed University), New Delhi, India
| | - Abida Parveen
- Centre for Translational and Clinical Research, Jamia Hamdard (Deemed University), New Delhi, India
| | - Gaurav
- Bioactive Natural Product Laboratory, Department of Pharmacognosy and Phytochemistry, School of Pharmaceutical Education and Research, Jamia Hamdard (Deemed University), New Delhi, India
| | - Rabea Parveen
- Department of Biosciences, Jamia Millia Islamia (Central University), New Delhi, India
| | - Minhaj Ahmad
- Department of Surgery, School of Unani Medical Education and Research, Jamia Hamdard (Deemed University), New Delhi, India
| |
Collapse
|
7
|
Antiviral Plants in View of Avicenna’s The Canon of Medicine and Modern Medicine Against Common Cold. ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY 2021; 1328:99-121. [DOI: 10.1007/978-3-030-73234-9_7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/09/2022]
|
8
|
Abstract
Chronic hepatitis C virus (HCV) infection is a significant public health problem, with a worldwide prevalence of approximately 170 million. Current therapy for HCV infection includes the prolonged administration of a combination of ribavirin and PEGylated interferon-α, for over a decade. This regimen is expensive and often associated with a poor antiviral response and unwanted side effects. A highly effective combination treatment is likely required for the future management of HCV infections and entry inhibitors could play an important role. Currently, no entry inhibitor has been licensed for the prophylactic treatment of hepatitis C. Therefore, additional agents that combat HCV infection are urgently needed and must be developed. Many phytochemical constituents have been identified that display considerable inhibition of HCV at some stage of the life cycle. This review will summarise the current state of knowledge on natural products and their possible activities in the context of HCV infection.
Collapse
Affiliation(s)
| | - Abeer Temraz
- Pharmacognosy Department College of Pharmacy, Umm Al-Qura University, Makkah, Saudi Arabia
- Pharmacognosy Department Faculty of Pharmacy For Girls, Al-Azhar University, Nasr City, Cairo, Egypt
| |
Collapse
|
9
|
Ganta KK, Chaubey B. Mitochondrial dysfunctions in HIV infection and antiviral drug treatment. Expert Opin Drug Metab Toxicol 2019; 15:1043-1052. [PMID: 31715109 DOI: 10.1080/17425255.2019.1692814] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/23/2023]
Abstract
Introduction: With the introduction of highly active anti-retroviral therapy (HAART), treatment of HIV infection has improved radically, shifting the concept of HIV disease from a highly mortal epidemic to a chronic illness which needs systematic management. However, HAART does not target the integrated proviral DNA. Hence, prolonged use of antiviral drugs is needed for sustaining life. As a consequence, severe side effects emerge. Several parameters involve in causing these adverse effects. Mitochondrial dysfunctions were pointed as common factor among them. It is, therefore, necessary to critically examine mitochondrial dysfunction in order to understand the side effects.Areas covered: There are many events involved in causing drug-induced side-effects; in this review, we only highlight mitochondrial dysfunctions as one of the events. We present up-to-date findings on mitochondrial dysfunction caused by HIV infection and antiviral drug treatment. Both in vivo and in vitro studies on mitochondrial dysfunction like change in morphology, membrane depolarization, mitophagy, mitochondrial DNA depletion, and intrinsic apoptosis have been discussed.Expert opinion: Mitochondrial dysfunction is associated with severe complications that often lead to discontinuation or change in treatment regimen. Prior knowledge of side effects of antiviral drugs would help in better management and future research should focus to avoid mitochondrial targeting of antiviral drugs while maintaining their antiviral properties.
Collapse
Affiliation(s)
- Krishna Kumar Ganta
- Functional Genomics Lab, Centre for Advanced Study, Department of Botany, University of Calcutta, Kolkata, India
| | - Binay Chaubey
- Functional Genomics Lab, Centre for Advanced Study, Department of Botany, University of Calcutta, Kolkata, India
| |
Collapse
|
10
|
Jugran AK, Rawat S, Bhatt ID, Rawal RS. Valeriana jatamansi: An herbaceous plant with multiple medicinal uses. Phytother Res 2019; 33:482-503. [PMID: 30663144 DOI: 10.1002/ptr.6245] [Citation(s) in RCA: 44] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/12/2018] [Revised: 09/26/2018] [Accepted: 11/03/2018] [Indexed: 01/22/2023]
Abstract
Valeriana jatamansi Jones (Family: Caprifoliaceae), a high value medicinal plant, was distributed in many countries of Asia. The species possesses important valepotriates and is a good source of flavones or flavone glycosides, lignans, sesquiterpenoids or sesquiterpenoid glycoside, bakkenolide type sesquiterpenoids, phenolic compounds, terpinoids, etc. The use of the species in traditional and modern medicines is well known. For instance, V. jatamansi is very important for its insect repelling and antihelmethic properties. Similarly, sedative, neurotoxic, cytotoxic, antidepressant, antioxidant, and antimicrobial activities of the species in various ailments in the indigenous system of medicine, particularly in Asia, are reported. This review focuses on the detailed phytochemical composition, medicinal uses, and pharmacological properties of V. jatamansi along with analysis of botanical errors in published literature and reproducibility of the biomedical researches on this multipurpose herbaceous species.
Collapse
Affiliation(s)
- Arun K Jugran
- G. B. Pant National Institute of Himalayan Environment and Sustainable Development, Garhwal Regional Centre, Srinagar, Uttarakhand, India
| | - Sandeep Rawat
- Centre for Biodiversity Conservation and Management (CBCM), G. B. Pant National Institute of Himalayan Environment and Sustainable Development, Kosi-Katarmal, Almora, Uttarakhand, India
| | - Indra D Bhatt
- Centre for Biodiversity Conservation and Management (CBCM), G. B. Pant National Institute of Himalayan Environment and Sustainable Development, Kosi-Katarmal, Almora, Uttarakhand, India
| | - Ranbeer S Rawal
- Centre for Biodiversity Conservation and Management (CBCM), G. B. Pant National Institute of Himalayan Environment and Sustainable Development, Kosi-Katarmal, Almora, Uttarakhand, India
| |
Collapse
|
11
|
Reddy BU, Mullick R, Kumar A, Sharma G, Bag P, Roy CL, Sudha G, Tandon H, Dave P, Shukla A, Srinivasan P, Nandhitha M, Srinivasan N, Das S. A natural small molecule inhibitor corilagin blocks HCV replication and modulates oxidative stress to reduce liver damage. Antiviral Res 2018. [DOI: 10.1016/j.antiviral.2017.12.004 pmid: 29224736] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
|
12
|
Reddy BU, Mullick R, Kumar A, Sharma G, Bag P, Roy CL, Sudha G, Tandon H, Dave P, Shukla A, Srinivasan P, Nandhitha M, Srinivasan N, Das S. A natural small molecule inhibitor corilagin blocks HCV replication and modulates oxidative stress to reduce liver damage. Antiviral Res 2017; 150:47-59. [PMID: 29224736 DOI: 10.1016/j.antiviral.2017.12.004] [Citation(s) in RCA: 35] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/24/2017] [Revised: 12/01/2017] [Accepted: 12/06/2017] [Indexed: 02/07/2023]
Abstract
Hepatitis C virus (HCV) infection causes chronic liver disease, which often leads to hepatocellular carcinoma. Earlier, we have demonstrated anti-HCV property of the methanolic extract of Phyllanthus amarus, an age-old folk-medicine against viral hepatitis. Here, we report identification of a principal bioactive component 'corilagin', which showed significant inhibition of the HCV key enzymes, NS3 protease and NS5B RNA-dependent-RNA-polymerase. This pure compound could effectively inhibit viral replication in the infectious cell culture system, displayed strong antioxidant activity by blocking HCV induced generation of reactive oxygen species and suppressed up-regulation of NOX4 and TGF-β mRNA levels. Oral administration of corilagin in BALB/c mice demonstrated its better tolerability and systemic bioavailability. More importantly, corilagin could restrict serum HCV RNA levels, decrease collagen deposition and hepatic cell denaturation in HCV infected chimeric mice harbouring human hepatocytes. Taken together, results provide a basis towards developing a pure natural drug as an alternate therapeutic strategy for restricting viral replication and prevent liver damage towards better management of HCV induced pathogenesis.
Collapse
Affiliation(s)
- B Uma Reddy
- Department of Microbiology and Cell Biology, Indian Institute of Science, Bangalore, 560012, India
| | - Ranajoy Mullick
- Department of Microbiology and Cell Biology, Indian Institute of Science, Bangalore, 560012, India
| | - Anuj Kumar
- Department of Microbiology and Cell Biology, Indian Institute of Science, Bangalore, 560012, India
| | - Geetika Sharma
- Department of Microbiology and Cell Biology, Indian Institute of Science, Bangalore, 560012, India
| | - Paromita Bag
- Department of Microbiology and Cell Biology, Indian Institute of Science, Bangalore, 560012, India
| | - Chaitrali Laha Roy
- Department of Microbiology and Cell Biology, Indian Institute of Science, Bangalore, 560012, India
| | - Govindarajan Sudha
- Molecular Biophysics Unit, Indian Institute of Science, Bangalore, 560012, India
| | - Himani Tandon
- Molecular Biophysics Unit, Indian Institute of Science, Bangalore, 560012, India
| | - Pratik Dave
- Department of Microbiology and Cell Biology, Indian Institute of Science, Bangalore, 560012, India
| | - Ashutosh Shukla
- Department of Microbiology and Cell Biology, Indian Institute of Science, Bangalore, 560012, India
| | - Priyanka Srinivasan
- Department of Microbiology and Cell Biology, Indian Institute of Science, Bangalore, 560012, India
| | - Madhusudhan Nandhitha
- Department of Microbiology and Cell Biology, Indian Institute of Science, Bangalore, 560012, India
| | | | - Saumitra Das
- Department of Microbiology and Cell Biology, Indian Institute of Science, Bangalore, 560012, India.
| |
Collapse
|